Antiparkinsons Flashcards

1
Q

What is the epidemiology of Parkinson’s Disease (PD)?

A
  • SG 0.3% for population aged >50yrs
  • young-onset PD: age 21-40, affects 5-10% of PD
  • juvenile-onset PD: <20yo, higher freq of genetically inherited PD amongst this grp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the pathophysiology of PD?

A
  • “impaired garbage disposal system”
  • impaired clearing of abnormal/damaged intracellular proteins by ubiquitin-proteasomal system
  • Failure to clear toxic proteins -> accumulation of aggresomes –> apoptosis
  • Lewy bodies = aggresome, containing alpha-synuclein and ubiquitin (bad, abnormally aggregated)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IMPT what is the main pathophysiology of PD?

A
  • degeneration of dopaminergic neurons w Lewy body inclusions in substantia nigra
    (other sites: locus ceruleus, cortical association areas, hypothalamic neurons, sympathetic ganglia parasympathetic neurons, olfactory bulb)
  • substantia nigra has dopaminergic projections to basal ganglia (impt in controlling movement)
  • basal ganglia faciliates and modulates motor movements initiated by motor cortex.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Is there any diagnosis of PD?

A
  • no reliable diagnostic marker for PD
  • diagnosis and diagnosis criteria based on: presence of clinical features, and the exclusion of alternative diagnoses
  • PD is the MAIN cause of parkinsonism; however, 10-25% of pts w parkinsonian syndromes don’t have PD
  • common differential diagnoses are the atypical parkinsonian disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

IMPT What are the 3 cardinal features of PD?

A
  • rest tremors
  • rigidity
  • bradykinesia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are some non-motor manifestations of PD?

A
  • autonomic, neuropsychiatric, olfactory, and sensory
  • common in PD; 88% of pts have at least one nonmotor smx and 11% w 5 nonmotor smx
  • more prominent in later stages of PD
  • Relatively resistant to, and may be worsened by dopaminergic agents
  • Cause significant disability
  • Often neglected in PD management
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is the course of disease?

A
  • progressive disorder
  • rate of disability progression is most marked in the early years of the disease.
  • significant disability 10-15 yrs after onset
  • at later stages, PD pts become increasingly dependent in their activities of daily living
  • Motor fluctuation, dyskinesia, and non-motor smx (e.g. falls, postural instability, postural hypotension, confusion, dementia, suboptimal nutrition, speech and sleep disorders) are common at later stages
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When is medication is started for PD pts?

A
  • individualised
  • early symptomatic disease without complications may not even need oral med if coping well
  • if taking, go slow, start low
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IMPT What is levodopa?

A
  • gold standard
  • dopamine precursor, “2-in-1” preparation with PERIPHERAL decarboxylase inhibitors
  • combi
    ~ madopar: levodopa + benserazide
    ~ sinemet: levodopa + carbidopa
  • available as regular form or long acting form (HBS
    or CR) (HBS = Hydrodynamically Balanced System; hbs Madopar)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the MOA of levodopa?

A

Levodopa is converted to dopamine via the action of DOPA decarboxylase.

This occurs both in the peripheral circulation and in the central nervous system after levodopa has crossed the blood brain barrier.

L-dopa needed as precursor in syn for dopamine
L-dopa needed in the brain so that dopamine can be syn with the enzyme dopa-decarboxylase
If l-dopa converted to dopamine in the peripheral, cannot cross BBB into brain

The peripheral decarboxylase inhibitors: Prevent L-dopa to convert to dopamine before entering BBB –> L-dopa can enter BBB and then converted to Dopamine –> thus lower dose of levodopa to get the same effect
Give more precursor to remaining neurons –> convert easier and produce inc of dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

IMPT what are the side effects of levodopa?

A
  • short-term: N/V, postural hypotension

- long-term: motor fluctuations and DYSKINESIA (10%/yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IMPT Is it okay to give levodopa? risk of dyskinesia?

A

although levodopa is the most efficacious drug for the symptomatic management of both early and late PD, the dose of levodopa should be kept to a MINIMUM necessary to achieve GOOD MOTOR FUNCTION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IMPT what is an example of an Anticholinergic?

A

Trihexyphenidyl (Artane) 2-15mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IMPT what are the advantages of trihexyphenidyl?

A
  • may be effective in controlling tremor

- peripherally acting agents may be useful in treating sialorrhea (excessive secretion of saliva)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IMPT what are the side effects of trihexyphenidyl?

A

Dry mouth, sedation, constipation, urinary retention, delirium, confusion, hallucinations

(esp in elderly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IMPT how do we take trihexyphenidyl?

A
  • as symptomatic monotherapy OR as an adjunct to levodopa (lower dose to be used) to treat tremors and stiffness in PD
17
Q

IMPT What is an example of MAO-B inhibitor?

A
  • Selegiline (Jumex)
  • Rasagiline

Remember the drug name

18
Q

IMPT What is the MOA of selegiline?

A
  • mild antiparkinson activity
  • inhibits enzyme monoamine oxidase B, interferes with the breakdown of dopamine
  • lab studies suggest that it may delay the nigral brain cell degeneration (Disease-modifying effect –> reduce the rate of degeneration)
19
Q

IMPT what are the side effects for selegiline?

A
  • heartburn, LOA, nausea, constipation, dizziness, anxiety, HA, palpitation, insomnia, confusion, nightmares, visual hallucination
20
Q

IMPT how do you take selegiline?

A

symptomatic monotherapy and may be used in early stages of PD

21
Q

IMPT What are examples of Catechol-O-methyltransferase (COMT) inhibitors?

A
  • Entacapone (Comtan) or Tolcapone (Tasmar)

Remember the drug name

22
Q

IMPT What is the MOA of COMT inhibitors?

A
  • blocks an enzyme that converts levodopa into an inactive form
  • more levodopa is available to enter the brain
  • ONLY EFFECTIVE IF USED WITH LEVODOPA
  • Inc duration of each dose of levodopa, is beneficial in treating ‘wearing off’ responses
23
Q

IMPT what are the side effects of COMT inhibitors?

A
  • inc abnormal movements (dyskinesias)
  • liver dysfn (tolcapone)
  • nausea, diarrhoea
  • urinary discolouration
  • visual hallucinations
  • daytime drowsiness, sleep disturbances
24
Q

IMPT what are examples of dopamine agonists?

A
  • Bromocriptine (Parlodel)
  • Pergolide (Celance, Permax)
  • Piribedil (Trivastal Retard)
  • Ropinirole (Requip)
  • Pramipexole (Sifrol)
    • remember the 3 names
25
Q

IMPT what is the MOA of dopamine agonists?

A
  • act directly on dopamine receptors in the brain to reduce the smx of PD
  • Antiparkinson effects not superior to levodopa (levodopa is still the GOLD standard)
  • prevent/delay onset of motor complication
  • adjunct or monotherapy
26
Q

IMPT What are the side effects of Dopamine agonists?

A
  • Similar to levodopa
  • short-term: N/V, postural hypotension
  • long-term: motor fluctuations and DYSKINESIA (10%/yr)
  • ‘ergot’ derivative - fibrosis
  • pedal oedema
  • somnolence with ropinirole, pramipexole
  • arrhythmia
  • Pergolide - restrictive valvular heart disease
27
Q

IMPT How to use dopamine agonists? mono or adjunct?

A

Efficacious as symptomatic monotherapy. Also used as adjunct to levodopa in PD treatment

  • in younger PD pts, should commence with dopamine agonists first rather than levodopa (milder SE)
28
Q

IMPT what is Amantadine?

A
  • antiviral agent
  • mild antiparkinsonian effect (tremor, rigidity, bradykinesia, dyskinesia)
  • Given mono or adjunct to levodopa
29
Q

IMPT what is the MOA of Amandtadine?

A
  • enhance release of stored dopamine
  • inhibit presynaptic uptake of catecholamine
  • dopamine receptor agonist
  • NMDA receptor antagonist (anti-glutamate)
  • antidyskinetics
  • CONSIDERED AS THERAPY TO REDUCE DYSKINESIA in pts w PD who have motor fluctuations
30
Q

IMPT what are the side effects of amantadine?

A
  • cognitive impairment (inability to concentrate), hallucination, insomnia, nightmares
  • livedo reticularis –> venule swelling due to thromboses –> mottled reticulated discolouration of limbs

Nervous, anxiety, agitation, insomnia, difficult in concentrating and exacerbation of pre-existing seizure disorders and psychiatric smx in pts with schiropeneia and PD

Amantadine is limited by the need to screen pts for hx of seizures and psychiatric smx

Rare cases of severe skin rashes SJS, and suicidal ideation reported for amantadine

31
Q

IMPT What are the Key Drugs to remember?

A

Dopaminergic:

  1. Levodopa (+/- carbidopa)
  2. Entacapone/Tolcapone (COMT inhibitors)
  3. Selegiline/rasagiline (MAO-B inhibitor)
  4. Bromocriptine/ pergolide/ ropinirole (Dopamine agonists)

Non-dopaminergic: Trihexyphenidyl (Anticholinergic)

Mixed MOA: amantadine